

Companion Diagnostics: Technologies and Markets

Market Research Report | 2024-04-23 | 121 pages | BCC Research

AVAILABLE LICENSES:

- Single User License \$5500.00
- 2-5 Users License \$6600.00
- Site License \$7920.00
- Enterprise License \$9504.00

Report description:

Description

Report Scope

The current report provides detailed coverage of the companion diagnostics market. This report highlights the current and future market potential of companion diagnostics, and it includes a detailed analysis of the drivers, opportunities, restraints, and challenges in the market. The report details the companion diagnostics market share based on product and service, type of test, technology, and application. The market's products and services is segmented into instruments, consumables, and services. It is categorized based on the type of test into commercial CDx and lab-developed tests (LDT)-CDx. Based on technology, the market is segmented into polymerase chain reaction, immunohistochemistry, next-generation sequencing, in situ hybridization, genotyping, immunoassays, exosomes, others, and services market. Based on application, the CDx market is categorized into cancer, neurologic disorders, cardiovascular disease, infectious disease, and others. Based on end users, the companion diagnostics market is segmented into clinical laboratories, pharmaceutical companies, contract research organizations (CROs), and other end users. The report also includes company profiles of the major players in the companion diagnostics market, with details about each company's business segments, financials, product portfolios, and recent developments. By geographical region, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. The North America region includes the U.S. and Canada; Europe includes Germany, the U.K., Italy, France, and the Rest of Europe; Asia-Pacific includes China, India, Japan, and the Rest of Asia-Pacific. For market estimates, data has been provided for 2020 and

2021 as the historic years, 2022 as the base year, and 2028 as the forecast year.

Report Includes

- 54 data tables and 59 additional tables
- Overview and an analysis of the global markets for companion diagnostics (CDx).
- Analyses of the global market trends, with historical market revenue data (sales figures) from 2021 to 2022, estimates for 2023, forecasts for 2024, and projections of compound annual growth rates (CAGRs) through 2028.
- A look at the current and future market potential of companion diagnostics along with the market dynamics, competitive

Scotts International. EU Vat number: PL 6772247784

landscape and regulatory scenario.

- Estimate of the market size and revenue forecast for the global CDx market, and corresponding market share analysis based on product and services, test type, technology, application, end user and region.
- Discussion of the market opportunities for CDx products by identification of high-growth applications in different therapeutic areas, with a focus on the largest and fastest-expanding markets for diseases.
- Analysis of recent market developments and clinical trials, as well as the leading companies engaged in R&D and product developments in CDx reagents.
- Discussion of the importance of ESG in the CDx industry, including consumer attitudes, the impact of ESG on company performance, ESG score analysis, and ESG practices followed by leading companies.
- Review of key patent grants and patent applications related to CDx.
- Identification of the major vendors along with an analysis of the competitive intelligence, including companies' market shares, recent M&A activity, and venture funding outlook.
- Company profiles of major players within the industry, including F. Hoffmann-La Roche Ltd., Agilent Technologies Inc., and OIAGEN

Executive Summary

Summary:

The global market for companion diagnostics is estimated to increase from \$7.6 billion in 2023 to reach \$15.4 billion by 2028, at a compound annual growth rate (CAGR) of 15.2% from 2023 through 2028.

Table of Contents:

Table of Contents

Chapter 1 Executive Summary

Market Outlook

Scope of Report

Market Summary

Highlights of the Market for Companion Diagnostics (CDx)

Chapter 2 Market Overview

Introduction

History

Regulatory Landscape

Companion Diagnostics Regulations in the U.S.

Companion Diagnostics Regulations Outside the U.S.

LDT-CDx Regulation

Chapter 3 Market Dynamics

Market Dynamics

Market Drivers

Market Restraints

Market Opportunities

Market Challenges

Chapter 4 Emerging Technologies and Developments

Emerging Technologies

Multiplex Testing

Next-Generation Sequencing (NGS)

Digital PCR

Liquid Biopsy

Scotts International, EU Vat number: PL 6772247784

Artificial Intelligence

Chapter 5 Market Segmentation Analysis

Segmental Breakdown

Global Market for Companion Diagnostics by Product and Service

Market Share and Forecast

Instruments

Consumables

Services

Global Market for Companion Diagnostics by Type of Test

Market Share and Forecast

LDT-CDx

Commercial CDx

Global Market for Companion Diagnostics by Technology

Market Share and Forecast

Polymerase Chain Reaction

Immunohistochemistry

Next-Generation Sequencing

In Situ Hybridization

Genotyping

Immunoassays

Exosomes

Others

Services

Global Market for Companion Diagnostics by Application

Market Share and Forecast

Cancer

Market for the Application of CDx in Cancer by Type

Neurologic Disorders

Cardiovascular Disease

Infectious Diseases

Other Diseases

Market Breakdown by End User

Market Share and Forecast

Clinical Laboratories

Pharmaceutical Companies

Contract Research Organizations (CROs)

Other End Users

Geographic Breakdown

Global Market for Companion Diagnostics by Region

North America

The U.S.

Canada

Europe

Germany

The U.K.

France

Italy

Scotts International, EU Vat number: PL 6772247784

Rest of Europe

Asia-Pacific

China

Japan

India

Rest of Asia-Pacific

Rest of the World

Chapter 6 Competitive Intelligence

Market Share Analysis

Leading Market Players in Companion Diagnostics Market, by Technology

Grants and Funding in Companion Diagnostics

Recent Developments of Key Market Players

Clinical Trials Analysis

Clinical Trials Analysis, by Type of Study

Clinical Trials Analysis, by Status

Clinical Trials Analysis, by Phase

Clinical Trials Analysis, by Region

Patent Analysis

Patents, by Year

Patents, by Top Applicant

Patents, by Top Owner

Patents, by Jurisdiction

Chapter 7 Sustainability in Companion Diagnostics: ESG Perspective

Introduction to ESG

Sustainability in the Companion Diagnostics Industry: An ESG Perspective

Key ESG Issues

Concluding Remarks from BCC

Chapter 8 Appendix

Methodology

References

Company Profiles

ABBOTT

AGILENT TECHNOLOGIES INC.

ARUP LABORATORIES

BIOMERIEUX

DANAHER CORP.

F. HOFFMANN-LA ROCHE LTD.

ILLUMINA INC.

MYRIAD GENETICS INC.

QIAGEN

THERMO FISHER SCIENTIFIC INC.



Print this form

To place an Order with Scotts International:

Companion Diagnostics: Technologies and Markets

Market Research Report | 2024-04-23 | 121 pages | BCC Research

ORDER FORM:		
Select license	License	Price
	Single User License	\$5500.00
	2-5 Users License	
	Site License	\$7920.00
	\$9504.00	
		VAT
		Total
	ant license option. For any questions please contact support@scotts-international.com	
** VAT will be added a	at 23% for Polish based companies, individuals and EU based companies who are unable	
]** VAT will be added a	et 23% for Polish based companies, individuals and EU based companies who are unable	
]** VAT will be added a Email* First Name*	et 23% for Polish based companies, individuals and EU based companies who are unable	
I** VAT will be added a Email* First Name* ob title* Company Name*	Phone* Last Name*	
** VAT will be added a Email* First Name* ob title*	Phone* Last Name* EU Vat / Tax ID / NIP number*	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com

Signature

Scotts International. EU Vat number: PL 6772247784